Cargando…

N(3)-o-toluyl-fluorouracil inhibits human hepatocellular carcinoma cell growth via sustained release of 5-FU

PURPOSE: N(3)-o-toluyl-fluorouracil (TFU), the prodrug of 5-fluorouracil (5-FU), is the metabolite of N(1)-acetyl-N(3)-o-toluyl-fluorouracil (atofluding). In the present study, we aimed to evaluate the efficacy of TFU on the inhibition of human hepatocellular carcinoma cells via sustained release of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Xiaofan, Zhong, Julia Li, Liu, Wei, Gao, Zuhua, Xue, Xia, Yue, Pan, Wang, Limei, Zhao, Cuirong, Xu, Wenfang, Qu, Xianjun
Formato:	Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2009
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2854362/ https://www.ncbi.nlm.nih.gov/pubmed/19756602 http://dx.doi.org/10.1007/s00280-009-1128-0

Ejemplares similares

Preclinical studies of N(3)-O-toluyl-fluorouracil-loaded lipid-based nanosuspensions in H(22)-bearing mice
por: Zhang, Juan, et al.
Publicado: (2014)

Fluorouracil (5-FU)-induced Cardiomyopathy
por: Thalambedu, Nishanth, et al.
Publicado: (2019)

Phase II study of 5-fluorouracil (5-FU) and high dose folinic acid (HDFA) in hepatocellular carcinoma.
por: Zaniboni, A., et al.
Publicado: (1988)

Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery
por: De Angelis, Paula M, et al.
Publicado: (2006)

Effect of Skimmed Milk on the Absorption and Metabolism of5-Fluorouracil (5-FU) in Animals
por: Ahmad, Maqsood, et al.
Publicado: (2012)

A unique presentation of 5-fluorouracil (5-FU) induced cerebral encephalopathy
por: Naik, Shailendra S, et al.
Publicado: (2020)

Pharmacokinetics and pharmacodynamics of locoregional 5 fluorouracil (5FU) in advanced colorectal liver metastases.
por: Goldberg, J. A., et al.
Publicado: (1988)

Transcriptomic and network pharmacology approaches revealed possible mechanisms underlying the 5-fluorouracil (5-FU)-sensitizing effect of Xuan-Fu-Hua decoction treatment on liver cancer cells
por: Luo, Wen-Zhao, et al.
Publicado: (2022)

The efficacy and safety of cardio-protective therapy in patients with 5-FU (Fluorouracil)-associated coronary vasospasm
por: Zafar, Amna, et al.
Publicado: (2022)

Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer
por: Saini, A, et al.
Publicado: (2003)

Clinical research of intraperitoneal implantation of sustained-release 5-fluorouracil in advanced colorectal cancer
por: Yuan, Hang, et al.
Publicado: (2015)

Preparation of 5-fluorouracil-loaded chitosan nanoparticles and study of the sustained release in vitro and in vivo
por: Sun, Li, et al.
Publicado: (2017)

Initial experience with topical fluorouracil (5-FU) for treatment of anal intraepithelial neoplasia (AIN) in HIV-positive patients
por: Snyder, Sean M, et al.
Publicado: (2010)

Over-activation of AKT signaling leading to 5-Fluorouracil resistance in SNU-C5/5-FU cells
por: Kim, Eun-Ji, et al.
Publicado: (2018)

Efficacy of Fractional Carbon Dioxide Laser (FCO(2)) with Intralesional 5-Fluorouracil (5-FU) in the Treatment of Keloids
por: Alhamzawi, Nabeel Kadhim
Publicado: (2021)

Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) ± folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients
por: Bensmaïne, M A, et al.
Publicado: (2001)

CS/Au/MWCNT nanohybrid as an efficient carrier for the sustained release of 5-FU and a study of its cytotoxicity on MCF-7
por: Nivethaa, E. A. K., et al.
Publicado: (2021)

Eukaryotic translation initiation factor 3 subunit G (EIF3G) resensitized HCT116/5-Fu to 5-fluorouracil (5-Fu) via inhibition of MRP and MDR1
por: Yang, Chenggang, et al.
Publicado: (2018)

Cisplatin/5-Fluorouracil (5-FU) Versus Carboplatin/Paclitaxel Chemoradiotherapy as Definitive or Pre-Operative Treatment of Esophageal Cancer
por: Steber, Cole, et al.
Publicado: (2021)

Targeting Lactate Dehydrogenase A with Catechin Resensitizes SNU620/5FU Gastric Cancer Cells to 5-Fluorouracil
por: Han, Jung Ho, et al.
Publicado: (2021)

No long-term survival benefit with sustained-release 5-fluorouracil implants in patients with stages II and III gastric cancer
por: Wu, Yun-Zi, et al.
Publicado: (2022)

Granuloma induced by sustained-release fluorouracil implants misdiagnosed as a hepatic tumor: A case report
por: BAI, DOU-SHENG, et al.
Publicado: (2014)

Formulation and characterization of 5-Fluorouracil enteric coated nanoparticles for sustained and localized release in treating colorectal cancer
por: Tummala, Shashank, et al.
Publicado: (2015)

Theoretical Encapsulation of Fluorouracil (5-FU) Anti-Cancer Chemotherapy Drug into Carbon Nanotubes (CNT) and Boron Nitride Nanotubes (BNNT)
por: Zarghami Dehaghani, Maryam, et al.
Publicado: (2021)

Recurrent Reversible Stroke-Like Encephalopathy After 5-Fluorouracil (5-FU) Chemotherapy: A Case Report and Literature Review
por: Yuwono, Kurniawan Agung, et al.
Publicado: (2023)

Spica Prunellae Extract Enhances Fluorouracil Sensitivity of 5-Fluorouracil-Resistant Human Colon Carcinoma HCT-8/5-FU Cells via TOP2α and miR-494
por: Fang, Yi, et al.
Publicado: (2019)

Retrospective Cohort Study of Intraoperative Administration of Sustained-Release 5-Fluorouracil Implants in Advanced Gastric Cancer Patients
por: Ge, Jie, et al.
Publicado: (2021)

Downregulation of δ opioid receptor by RNA interference enhances the sensitivity of BEL/FU drug-resistant human hepatocellular carcinoma cells to 5-FU
por: TANG, BO, et al.
Publicado: (2016)

Downregulation of δ opioid receptor by RNA interference enhances the sensitivity of BEL/FU drug-resistant human hepatocellular carcinoma cells to 5-FU
por: Tang, Bo, et al.
Publicado: (2018)

Application of 5-Fluorouracil-Polycaprolactone Sustained-Release Film in Ahmed Glaucoma Valve Implantation Inhibits Postoperative Bleb Scarring in Rabbit Eyes
por: Bi, Xiu-Zeng, et al.
Publicado: (2015)

Association between ERCC1 and TS mRNA levels and disease free survival in colorectal cancer patients receiving oxaliplatin and fluorouracil (5-FU) adjuvant chemotherapy
por: Li, Sheng, et al.
Publicado: (2014)

Inhibition of G9a promoted 5-fluorouracil (5-FU) induced gastric cancer cell apoptosis via ROS/JNK signaling pathway in vitro and in vivo
por: Lou, Haizhou, et al.
Publicado: (2019)

A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases
por: Bathe, Oliver F, et al.
Publicado: (2009)

Synergistic combination of PMBA and 5-fluorouracil (5-FU) in targeting mutant KRAS in 2D and 3D colorectal cancer cells
por: Qayum, Arem, et al.
Publicado: (2022)

Targeting REV7 effectively reverses 5-FU and oxaliplatin resistance in colorectal cancer
por: Sun, Xianjun, et al.
Publicado: (2020)

[Retracted] Downregulation of δ opioid receptor by RNA interference enhances the sensitivity of BEL/FU drug‑resistant human hepatocellular carcinoma cells to 5‑FU
por: Tang, Bo, et al.
Publicado: (2023)

5-FU Metabolism in Cancer and Orally-Administrable 5-FU Drugs
por: Miura, Koh, et al.
Publicado: (2010)

Herbal medicine Guan Chang Fu Fang enhances 5-fluorouracil cytotoxicity and affects drug-associated genes in human colorectal carcinoma cells
por: YU, CHEN, et al.
Publicado: (2015)

Autophagy Inhibitor (LY294002) and 5-fluorouracil (5-FU) Combination-Based Nanoliposome for Enhanced Efficacy Against Esophageal Squamous Cell Carcinoma
por: Feng, Ye, et al.
Publicado: (2018)

Novel mutual prodrug of 5-fluorouracil and heme oxygenase-1 inhibitor (5-FU/HO-1 hybrid): design and preliminary in vitro evaluation
por: Salerno, Loredana, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_53f9fs6h87sep5ku7tfpti7ahk